CTOs on the Move

Seed Health

www.seed.com

 
Seed Health is a microbial sciences company pioneering applications of microbes for human and planetary health. In collaboration with leading academic researchers, we advance breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics, consumer health innovations and environmental solutions.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Seed Health raised $40M on 04/21/2021

Similar Companies

LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals is a Bozeman, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Skagit Valley Hospital

Skagit Valley Hospital is a Mount Vernon, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arzeda

Arzeda The Protein Design Company is a synthetic biology company.

TissueTech

TissueTech, Inc is a Biotechnology company headquartered in Miami, FL. TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. TissueTech offers its portfolio of amniotic membrane and umbilical cord-based tissue and device products through its commercial entities: BioTissue, Inc: the industry leader in regenerative tissue therapies for ocular surface diseases and disorders. Amniox Medical: a leading technology provider to the musculoskeletal and wound care markets.

Minaris Advanced Therapies

Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized LYFGENIA, a gene therapy for sickle cell disease. With a focus on collaboration, Minaris serves over 180 biotech and pharmaceutical clients, providing tailored solutions for their specific needs in regenerative medicine. Its facilities include expanded cleanroom capacity and analytical labs to support large-scale production.